Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy

Visit www.ecancer.org for more.
At a press conference at ESMO 2014, Dr Mok (The Chinese University of Hong Kong, Shatin, China) presents the results of a phase 3 trial which found that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.